Ciliary neurotrophic factor (CNTF), leukemia inhibiting factor (LIF), IL-11 and oncostatin M (OSM) boost IL-6 activity [62,63] and are the main downstream effectors, pointing to a potential theragnostic window, which could be exploited in treating the early phases of MM development [63] and supporting IL-6-mediated support for MM growth and survival [64]. The gene discussed is IL6; the disease is Miyoshi myopathy.